Author

J. N. Allan

Observed name: J.N. Allan

Institution: Weill Cornell Medicine

Observed institution: Weill Cornell Medicine

OpenAlex ID: A5000201928

144 | UPDATED EFFICACY/SAFETY OF THE BRUTON TYROSINE KINASE (BTK) DEGRADER BGB‐16673 IN RELAPSED/REFRACTORY (R/R) CLL/SLL: RESULTS FROM THE ONGOING PHASE 1 CaDAnCe‐101 STUDY

2025 · J. F. Seymour, R. D. Parrondo, et al. · Hematological Oncology · 5

436 | UPDATED EFFICACY/SAFETY OF BRUTON TYROSINE KINASE DEGRADER BGB‐16673 IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NHL: ONGOING PHASE 1 CaDAnCe‐101 RESULTS

2025 · P. L. Zinzani, A. M. Frustaci, et al. · Hematological Oncology · 1

147 | UPDATED EFFICACY & SAFETY OF BTK DEGRADER BGB‐16673 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (R/R WM): ONGOING PHASE 1 CaDAnCe‐101 RESULTS

2025 · A. M. Frustaci, J. F. Seymour, et al. · Hematological Oncology · 1

P670: Absence of Btk, Bcl2, and Plcg2 Mutations in Relapsing Chronic Lymphocytic Leukemia (cll) After First-line Treatment With Fixed-duration Ibrutinib (i) Plus Venetoclax (v)

2022 · L. J. Croner, J. N. Allan, et al. · HemaSphere · 1

Works count: 6

Citation count: 8

H-index: 1

I10-index: